QRxPharma Limited announced initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US. MoxDuo IR, an immediate-release Dual Opioid pain therapy, is a patented 3:2 fixed ratio combination of morphine and oxycodone.
“In just four years, we have successfully moved MoxDuo IR through clinical trials and NDA submission by demonstrating its effectiveness and safety. Achievement of this milestone clearly establishes the value of this Dual Opioid product to patients and prescribers as well as potential partners,” said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. “The timeframe and capital efficient manner in which these milestones were achieved are impressive accomplishments compared to conventional industry development and cost benchmarks.”
This NDA submission is based on a full clinical and manufacturing program for MoxDuo IR. As agreed with the FDA, the NDA for MoxDuo IR is being submitted under 505(b)(2) regulations wherein approval for a new drug may be obtained more efficiently because the approval process can rely upon historical data regarding its’ already approved components. A 505(b)(2) approval also provides commercial benefits because, in parallel to patents which cover MoxDuo until 2029, it affords to the sponsor additional regulatory market exclusivity, allowing companies to develop a marketing strategy with a brand consumers recognize and may prefer in a potentially wide-open market.
As agreed with the FDA during its pre-NDA meeting with the Company in March, 2011, the NDA manufacturing section filing initiated the NDA review and is classified as an ‘early submission’, enabling sponsors like QRxPharma to obtain a head-start on the overall review process, with the remaining technical documentation to follow in August. Approval of an NDA typically takes 10-12 months from submission. Later this year, the Company will augment the filing with additional safety information derived from the recently completed Study 022.
The US NDA package will serve as the core component of MoxDuo registration submissions in Europe, Australia, Canada and elsewhere. The Company believes that the recently completed Study 022 demonstrating a clinically significant reduction in respiratory depression, the major cause of death from opioids, will be attractive to regulators and prescribers and will also facilitate label claim advantages for MoxDuo IR when the European Marketing Authorisation Application (MAA) is submitted in 2012.
“To our best knowledge, QRxPharma’s NDA is only the second NDA filed with the FDA by a stand-alone Australian therapeutics company within the last decade. The Company is on track for product approval and sales in 2012 when MoxDuo IR is to be launched into the $8 billion US pain market,” added Dr. Holaday.
The development program included three pivotal Phase 3 studies for the treatment of moderate to severe post-operative pain. In head-to-head comparisons with morphine, oxycodone, Percocet, and placebo, more than 700 patients have been treated with MoxDuo IR in seven clinical trials over the Company’s successful Phase 3 program. Clinical data have consistently demonstrated that MoxDuo IR achieves equal or better pain relief with fewer incidences of moderate to severe side effects in those comparisons using current standards of care.
Date: July 18, 2011
Source: QRxPharma Limited
Filed Under: Drug Discovery